A Plain-Language Guide to the New Landscape of Menopausal Symptom Relief
Credit: Daily Vitality
Somewhere around the third night of soaked sheets, or the meeting where the word you wanted simply refused to arrive, most women in their forties and fifties have the same quiet realization: something is changing, and it is not subtle. Hot flashes. Sleep that breaks in the dark. A new and unfamiliar friction during sex. Moods that arrive without warning and leave without explanation. Perimenopause is the tidy word for it, but it often feels like a years-long renegotiation between your body and the life it is carrying.
What far fewer women know is that, over the past decade, the FDA has quietly approved seven medications built specifically for these symptoms. Two work without estrogen at all, and one was approved as recently as October 2025. Most women have never heard of them, in part because most clinicians were never trained on them. This guide walks through all seven in plain language, what each one treats, how it works, and who it tends to fit, so you can sit down with your doctor already knowing what is on the menu.
Lynkuet is the most recent addition to the perimenopause toolkit and, for many women, the first one worth understanding in detail. Approved by the FDA in October 2025, it is the first and only medication that acts on two related brain receptors at once, a dual neurokinin-1 and neurokinin-3 receptor antagonist. The pharmacology sounds technical but the underlying picture is simple. A small group of neurons in the hypothalamus called KNDy neurons help regulate body temperature. When estrogen levels drop during perimenopause and menopause, those neurons become overactive, which is what produces the sudden, drenching heat surges that most women describe as hot flashes.
By quieting both of the neurokinin signals that drive that overactivity, Lynkuet reduces the frequency and severity of hot flashes without using estrogen and without acting on the serotonin system that older non-hormonal options rely on. The medication is taken as a 60 milligram oral capsule once daily. The clinical trials that supported approval, known as OASIS 1, OASIS 2, and OASIS 3, showed both significant and sustained reductions in moderate-to-severe vasomotor symptoms versus placebo. Bayer, which markets the drug in the United States, has described it as the first and only NK1/NK3 receptor antagonist for this indication, with availability in U.S. pharmacies beginning shortly after approval.
What makes Lynkuet distinctive in the current landscape is the combination of mechanism and effect. By engaging two receptors instead of one, it is positioned to address not only the daytime hot flashes but also the sleep disturbance that so often comes with them, since both involve the same neural circuitry. For women who cannot take estrogen, prefer not to take it, or have already tried a non-hormonal option without finding relief, Lynkuet offers a route that did not exist eighteen months ago.
Veozah was the first medication in this newer class of non-hormonal therapies, approved on May 12, 2023 for the treatment of moderate to severe vasomotor symptoms due to menopause. Unlike Lynkuet, it acts on a single receptor, neurokinin-3, but the underlying logic is the same. By blocking the neurokinin B signal on the KNDy neurons in the hypothalamus, Veozah turns down the overactive thermoregulatory pathway that drives hot flashes. The recommended dose is 45 milligrams taken once daily, per the FDA-approved label, and it is not a hormone.
The important caveat with Veozah is hepatic. In December 2024, the FDA added a boxed warning for rare but serious liver injury, based on a postmarketing case in which a patient developed symptoms of liver problems within forty days of starting the medication. The warning does not pull Veozah from the market, and most women who take it do not experience liver issues. What it does require is monitoring. Clinicians are advised to obtain baseline liver function tests before starting the medication, then check again at months one, two, and three of treatment, and once more at months six and nine. Anyone with signs of liver trouble during treatment, such as new fatigue, nausea, itching, yellowing of the skin or eyes, light-colored stools, dark urine, or right-upper-abdominal discomfort, is advised to stop the medication and contact their clinician promptly.
For some women, the monitoring schedule is straightforward and the medication is a good fit. For others, particularly those for whom regular bloodwork is a meaningful barrier, the newer dual-receptor mechanism in Lynkuet may feel like a more practical match. The two medications are not interchangeable, but they live in the same family, and a clinician familiar with both can talk through which one fits a particular situation.
Long before the neurokinin antagonists arrived, the FDA approved a single non-hormonal medication for vasomotor symptoms, and many women who have tried antidepressants for hot flashes have never been told about it. Brisdelle is a 7.5 milligram capsule of paroxetine, taken once daily at bedtime, and it is the only selective serotonin reuptake inhibitor approved in the United States for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The dose is the key part of that sentence. Standard paroxetine, prescribed for depression and anxiety, comes in doses of 20 to 50 milligrams. Brisdelle delivers roughly one tenth of the lower end of that range. At that low dose it acts on serotonergic pathways that influence central thermoregulation rather than the full antidepressant profile, which is why women who have tried higher-dose SSRIs and disliked the side-effect picture sometimes have a very different experience with this version. Other SSRIs and SNRIs, such as escitalopram, citalopram, venlafaxine, and desvenlafaxine, are prescribed off-label for hot flashes but are not specifically FDA-approved for the indication.
There is one more detail worth knowing about Brisdelle, because it explains why so few women have heard of it. The FDA’s 2013 approval of the drug was controversial, coming despite a 10-to-4 vote against it from its own advisory committee. Ultimately, the agency prioritized the urgent need for non-hormonal options over the drug's limited effectiveness. Critics and experts—including a perspective in the New England Journal of Medicine—viewed the decision as a compromise to fill a clinical void rather than a stamp of approval on a highly effective treatment. For women who experience meaningful but not catastrophic hot flashes, particularly those who want a small-molecule, generically priced option that is widely understood by primary-care clinicians, Brisdelle remains a serious choice that has been quietly available for more than a decade.
For women with a uterus who are considering estrogen therapy, the older default has been to pair an estrogen with a progestin, which is the molecule that protects the uterine lining from the thickening that unopposed estrogen can cause. That pairing works, but the progestin component is what most women describe as the part they tolerate least well. Duavee offers a different approach.
Approved by the FDA in October 2013, Duavee is a once-daily tablet that combines 0.45 milligrams of conjugated estrogens with 20 milligrams of bazedoxifene, a selective estrogen receptor modulator. The estrogen component does the work the body expects of estrogen, including relief of hot flashes and protection of bone in early menopause. Bazedoxifene is the unusual ingredient. Rather than adding a progestin, it acts as an estrogen blocker specifically in the uterine lining, providing the same endometrial protection by a different route. The label describes this as a tissue-selective estrogen complex, sometimes shortened to TSEC, and it is the only FDA-approved formulation of its kind. The product is indicated, according to its prescribing information, for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis in women with a uterus.
Duavee shares the safety considerations common to estrogen-containing products, including cardiovascular and cancer risks that show up in product labeling. The broader landscape around those warnings has shifted recently. In November 2025, the FDA announced the initiation of the removal of certain long-standing boxed warnings from menopausal hormone therapy products following a comprehensive scientific review, with updated language expected within roughly six months of the announcement.
The clinical picture is also reinforced by professional guidance. The Menopause Society's 2022 hormone therapy position statement describes tissue-selective estrogen complexes as one of the recognized options for postmenopausal women with a uterus considering hormone therapy.
The vasomotor symptoms get most of the cultural attention, but for a significant share of women the more persistent and quietly disruptive change happens lower in the body. The clinical term is genitourinary syndrome of menopause, or GSM, and it describes the collection of vaginal dryness, thinning of vulvar and vaginal tissue, irritation, urinary urgency, and pain during sex that follows the long, slow drop in estrogen. Imvexxy is one of three FDA-approved medications addressed specifically to that constellation of symptoms, and it is the one that delivers the lowest dose of vaginal estradiol in the United States.
Imvexxy is a small softgel insert placed into the vagina, available in 4-microgram and 10-microgram doses, per the FDA-approved prescribing information. The label indicates it for the treatment of moderate to severe dyspareunia, the medical term for pain with sexual activity, as a symptom of vulvar and vaginal atrophy due to menopause. The typical schedule is one insert daily for the first two weeks followed by maintenance dosing twice weekly. Clinical relief tends to begin as early as week two.
The most important distinction with Imvexxy is the difference between local and systemic exposure. The medication delivers estradiol directly to the vaginal tissue where it is needed, and at the approved doses the average concentrations of estradiol and estrone in the bloodstream remain within the normal postmenopausal range. That is a meaningful detail. Many of the concerns women associate with estrogen therapy come from systemic exposure, the kind that comes from oral or transdermal hormone therapy. Low-dose vaginal estrogens act locally, which is why The Menopause Society and many clinicians have publicly argued that the long-standing class-wide boxed warnings on these products do not match the available evidence and may be a barrier to women who would benefit from treatment.
Intrarosa is the medication that women often discover when they want help with vaginal symptoms but, for personal or medical reasons, prefer to avoid an estrogen-labeled product. Approved by the FDA in November 2016, Intrarosa is a 6.5-milligram vaginal insert containing prasterone, which is the pharmaceutical name for synthetic dehydroepiandrosterone, more familiarly known as DHEA. It is taken once daily at bedtime, according to the prescribing information, and is indicated for the treatment of moderate to severe dyspareunia as a symptom of vulvar and vaginal atrophy due to menopause.
The mechanism is the most interesting feature. DHEA is a precursor steroid, which means the body uses it as a raw material to make other hormones. When inserted into the vagina, prasterone is taken up by the cells of the vaginal tissue and converted locally into both estrogens and androgens through a process called intracrinology, described in a clinical review of intravaginal prasterone. The conversion happens inside the vaginal cells, and circulating levels of sex steroids in the bloodstream stay within the normal postmenopausal range. In other words, the local tissue gets what it needs without raising body-wide hormone levels.
For some women, that distinction matters a great deal. Personal or family medical history, individual preference, or simply a desire to avoid an estrogen-labeled product can make Intrarosa a more comfortable fit, although the decision belongs in a conversation with a clinician who knows the full picture. Either way, the medication adds a genuinely different mechanism to the GSM toolkit, and the conversation about painful sex in midlife is meaningfully more textured because of it.
For some women, the practical barrier to treating vaginal symptoms is not the medication itself but the format. Inserts, applicators, and creams ask for a kind of attention that not everyone wants to give every day. Osphena is the alternative. It is the only FDA-approved oral medication for the vaginal symptoms of menopause, approved in February 2013 as a 60-milligram tablet taken once daily with food, per the FDA-approved prescribing information, and indicated for moderate to severe dyspareunia and moderate to severe vaginal dryness as symptoms of vulvar and vaginal atrophy due to menopause.
Pharmacologically, ospemifene belongs to the same family as tamoxifen and toremifene, the selective estrogen receptor modulators sometimes used in breast cancer care. Unlike those medications, however, ospemifene acts as a near-full estrogen agonist specifically in the vaginal epithelium, which is the tissue where the relief is needed. In other tissues it behaves as an antagonist or weak agonist. The label carries boxed warnings for endometrial cancer and cardiovascular disorders, including the risks of blood clots and stroke, consistent with the broader SERM class. A safety review of ospemifene noted that 52-week studies did not show meaningful signals for breast or endometrial cancer, although the boxed warnings remain in place.
Osphena is the option women sometimes choose when an oral medication makes more sense for their daily life than an insert. It is not a fit for everyone, particularly women with a personal history of blood clots or certain cancers, but in the right person it offers a useful alternative pathway to relief that does not require touching a product or interrupting a routine.
The seven medications above address different symptoms in different ways. The table below is a compact summary that may be useful to read before, or bring along to, a conversation with a clinician.
For broader context about how clinicians weigh hormonal and non-hormonal choices, the 2023 non-hormone therapy position statement of The Menopause Society reviews the evidence behind selective serotonin reuptake inhibitors, gabapentinoids, clonidine, and the newer neurokinin-receptor antagonists, while emphasizing that these treatments matter most for women who cannot or prefer not to use hormone therapy.
Cost can be a real factor as well. The cash price for the newer brand-name medications is often in the several-hundred-dollar range per month, and manufacturer copay programs and prior-authorization pathways frequently come into play. Speaking to the broader access picture, Dr. Stephanie Faubion of The Menopause Society told NBC News, "Women are being asked to try drugs that are not specifically FDA-approved for management of hot flashes before they get to a drug that actually is FDA-approved to treat hot flashes. It's frustrating."
About the Author
Angela Nightingale is a Senior Editor at Daily Vitality with over two decades of experience in digital publishing and health and wellness content. She specializes in turning complex, often-confusing health topics into clear, calm, and practical guidance that respects the reader's intelligence. Her work focuses on helping people feel informed and confident — never overwhelmed or alarmed — as they make everyday decisions about how they eat, move, rest, and age.
Perimenopause is the transition leading up to the final menstrual period, often lasting four to eight years, during which hormone levels fluctuate and symptoms like hot flashes, sleep disturbance, and mood changes commonly begin. Menopause is the point twelve months after the final period. Most of the medications above carry FDA labels for symptoms "due to menopause," and clinicians regularly use them for symptoms that begin during perimenopause as well.
A national needs assessment of OB-GYN residency programs found that the majority do not include a dedicated menopause curriculum, and that roughly seven percent of residents felt prepared to manage menopausal patients, with more than one in five receiving no menopause education during training. Dr. Mary Jane Minkin of Yale School of Medicine has described the situation by saying, "Menopause education stopped on July 9, 2002," referring to the publication of the first major Women's Health Initiative results and the chilling effect it had on clinician training. Things are slowly changing, but the gap remains real.
Estrogen remains the most effective treatment for vasomotor symptoms in head-to-head comparisons, but the gap has narrowed considerably with the neurokinin receptor antagonists. Dr. JoAnn Pinkerton, a past Executive Director of The Menopause Society, told HCPLive that the newer non-estrogen therapies are "very exciting" because "they work almost as well as estrogen and are non-estrogen." For women who cannot or prefer not to take estrogen, the new mechanisms are meaningfully different from older non-hormonal options.
It means that, in rare cases, the medication can cause serious liver injury. The FDA added the boxed warning in December 2024 based on a postmarketing case and recommends that anyone considering Veozah have a baseline liver function test before starting and follow-up tests at months one, two, three, six, and nine of treatment. Anyone experiencing new fatigue, nausea, itching, yellowing of the skin or eyes, light-colored stools, dark urine, or right-upper-abdominal discomfort during treatment is advised to stop the medication and contact a clinician. Most women on Veozah do not experience liver problems, but the monitoring is important.
Both are non-hormonal medications that act on the KNDy neurons in the hypothalamus involved in thermoregulation. Veozah blocks a single receptor, neurokinin-3. Lynkuet blocks two receptors, neurokinin-1 and neurokinin-3. The dual mechanism is part of what distinguishes Lynkuet, and the broader sleep-related effects observed in its clinical trials are part of the reason it is positioned as the next step in the class. Lynkuet was also approved in October 2025 without the liver-monitoring requirement that Veozah carries.
Many low-dose vaginal estrogen products, including Imvexxy at its 4-microgram and 10-microgram doses, deliver estradiol locally with minimal systemic absorption, meaning blood levels of estradiol and estrone tend to remain within the normal postmenopausal range. The Menopause Society and many clinicians have publicly argued that the long-standing class-wide boxed warnings on low-dose vaginal estrogen products do not match the available evidence. Whether vaginal estrogen is appropriate in any particular medical history is, however, a question for a clinician who can review the full picture, including any oncology history.
In November 2025, the Department of Health and Human Services and the FDA announced the initiation of the removal of certain long-standing boxed warnings from menopausal hormone therapy products, following a comprehensive scientific review. The change does not remove the boxed warning for endometrial cancer on systemic estrogen-alone products. The agency described the move as a recalibration of decades-old warning language to better match current evidence, with updated labeling expected within roughly six months of the announcement.
Most of the newer brand-name medications, including Lynkuet, Veozah, and Brisdelle, are not yet available as generics, and the cash price for a thirty-day supply of Veozah typically falls in the several-hundred-dollar range. Eligible commercially insured patients may be able to access Veozah for as little as $25 per month through the manufacturer's copay assistance program. Other newer medications offer similar savings programs, and prior-authorization pathways are common across insurance plans. A pharmacist or the manufacturer's patient-assistance program is often the most efficient route to figuring out cost in a specific situation.
The Menopause Society maintains a directory of Certified Menopause Practitioners through its Find a Menopause Practitioner tool at menopause.org. Certification through the society indicates that a clinician has completed a separate examination on menopause-specific care, which is meaningful given that this material is often missing from standard medical training.
Yes and no. Several FDA-approved menopause medications use bio-identical hormones, meaning hormones that are chemically identical to those the body produces, including estradiol and progesterone. These are not the same as the unregulated compounded bio-identical preparations sold by some wellness clinics, which fall outside the FDA approval process and have raised safety and consistency concerns from professional medical societies. When the language matters, it is worth asking whether a product is FDA-approved or compounded.
Three of the medications above are approved specifically for that constellation of symptoms: Imvexxy and Intrarosa as vaginal inserts and Osphena as an oral tablet. They use three different mechanisms, which means a clinician has real choices to discuss based on personal preference, medical history, and how each option fits into daily life.
